ARKGARK Genomic Revolution ETF

Grow my money11y track recordRanked #695 of 3,055 in this goal

Seeks long-term growth of capital.

By ARK ETF Trust · Launched 2014

Annual Cost

0.75%

#4,069 of 6,040 · expensive

Fund Size

$2.0B

#791 of 6,040 · large

Return (1Y)

+94.3%

Track Record

11 years

#1,230 of 6,040 · established

Performance

Total-return NAV · USD

Growth of $10,000

$17,612+76.1%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Active selection

Sector

Health care

Focus

Biotech & Genomics

Holdings

By weight

Concentration

Top 10 holdings = 58.8% of fundmoderately concentrated

TEMPUS AI INC

9.4%

TWIST BIOSCIENCE CORP

9.0%

CRISPR THERAPEUTICS AG

8.9%

10X GENOMICS INC

5.8%

BEAM THERAPEUTICS INC

5.4%

ABSCI CORP

4.8%

NATERA INC

4.1%

ILLUMINA INC

4.0%

INTELLIA THERAPEUTICS INC

3.8%

PERSONALIS INC

3.6%

Asset allocation

Stocks

99.6%

Cash

0.4%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

45.0%High

Year-on-year price swings

Max drawdown

-83.6%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.50Decent risk-adjusted returns

Sortino (3Y)

0.77Moderate downside risk

Listing

Exchange: Cboe BZX

Full fund details

Objective: Seeks long-term growth of capital.
Strategy: Actively manages a portfolio primarily invested in equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy, and consumer discretionary, that are relevant to the genomics revolution. Investments include micro-, small-, medium-, and large-cap companies in both developed and emerging markets.
Inception date: October 31, 2014
Fund family: ARK ETF Trust